Clinical observation of shenkang injection in treatment of partly chronic kidney disease in early stage
GAO Ai-min
AN Zhi
CHENG Yan-na
LUO Hua
WANG Yan-ni
Abstract：Objective To observe the clinical efficacy and safety of shenkang injection in treatment of partly chronic kidney disease ( chronic kidney disease,CKD 2 period) in early stage.Methods On the basis of stable blood pressure control,66 patients with CKD 2 disease were given shenkang injection for 4 courses with 30 days as a course.Clinical indices such as urea nitrogen( BUN),serum creatinine(Scr),cystatin-C (CysC),glomerular filtration rate( GFR),hemoglobin( Hb),urine protein quantity per 24 hours and fibrinogen were tested; clinical efficacy and adverse reactions were recorded.Results After treatment,the clinical efficiency was 80.3％.BUN,CysC,urine protein quantity per 24 hours and fibrinogen decreased greatly [(6.68 ±0.76) mmol/L vs (7.23 ±0.44) mmol/L,P ＜ 0.05 ; ( 6.12 ± 0.88 ) mmol/L vs ( 7.23 ± 0.44 ) mmol/L,P ＜ 0.01] ; there were significant differences of CysC of the 1st,2nd and 4th courses of treatment before and after treatment [( 1.11 ± 0.12 ),(0.94 ±0.11 ),(0.80 ±0.12)mg/L vs (1.34 ± 0.14)mg/L respectively,P ＜ 0.01]; there were significant differences of urine protein quantity per 24 hours and fibrinogen of the 4th courses of treatment before and after treatment,[P ＜ 0.05 and P ＜0.01,respectively].After treatment,GFR and Hb increased greatly.There were significant differences of GFR and Hb of the 2nd and 4th courses of treatment,compared with those of before-treatment[GFR:(77.4 ±9.2),(80.6 ± 8.8 ) ml/min vs ( 70.9 ± 9.3 ) ml/min,P ＜ 0.05.The adverse reactions showed no significant differences.Conclusion Shenkang injection is safe and effective in relieving CKD progress on CKD in the early stage.
Keywords：NephrologyGlomerulonephritisGlomerulonephritisIgARenal agentsShenkang injection
Publication Date：2012-01-01
Online Publishing Date：2026-09-14(First online date of this platform, not the publication date of the document)